CLINICAL TRIALS PROFILE FOR MIRVASO
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Mirvaso
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02249065 ↗ | Mirvaso in Use Study | Completed | Galderma Laboratories, L.P. | Phase 4 | 2014-09-01 | This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea. |
| NCT02289352 ↗ | Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea | Completed | Watson Laboratories, Inc. | Phase 3 | 2014-07-01 | A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea |
| NCT02289352 ↗ | Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea | Completed | Actavis Inc. | Phase 3 | 2014-07-01 | A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea |
| NCT02568111 ↗ | Brimonidine Tartrate for the Treatment of Injection Related Erythema | Withdrawn | Biogen | Phase 4 | 2016-02-01 | The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mirvaso
Condition Name
Clinical Trial Locations for Mirvaso
Trials by Country
Clinical Trial Progress for Mirvaso
Clinical Trial Phase
Clinical Trial Sponsors for Mirvaso
Sponsor Name
